We are actively involved in the Biosimilars market, working closely with manufacturers to help patients receive safe, cost-effective treatments.

Biosimilar treatments use alternative living enzymes to those found in their licensed counterparts, delivering treatments similar in quality, safety and efficacy without geographic distribution restrictions.

By choosing Biosimilars, our customers can offer patients the latest treatments in geographies where brand-name medicines are not yet available or where the cost of providing those treatments is prohibitively expensive.

With direct links to the manufacturers, our customers can have complete confidence in the quality and safety of these innovative products while manufacturers can also benefit from our specialist supply networks to access biosimilar enzymes for research and development programmes.

For further information or to discuss your specific requirements, please email haley.whitfield@client-pharma.com.